{'fraction_non_alphanumeric': 0.037821482602118005, 'fraction_numerical': 0.0030257186081694403, 'mean_word_length': 5.245283018867925, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A HCBP1 peptide conjugated ruthenium complex for targeted therapy of hepatoma.

An HCBP1 peptide-ruthenium conjugate (Ru-β-Ala-FQHPSFI) as a potential candidate for targeted therapy of hepatoma was synthesized. Ru-β-Ala-FQHPSFI shows drastically enhanced cytotoxicity and high selectivity for hepatoma cells versus noncancer liver cells. Raman imaging shows that this peptide-based drug can be taken up well by the hepatoma cells compared with the bare ruthenium complex (Ru) and the opposite sequence peptide-ruthenium conjugate (Ru-β-Ala-IFSPHQF). This study presents a new strategy for the construction of tumor-targeting metal-based anticancer therapeutics.